Details

Autor(en) / Beteiligte

• Wei, Jia
• Matthews, Philippa C.
• Stoesser, Nicole
• Maddox, Thomas
• Lorenzi, Luke
• Studley, Ruth
• Bell, John I.
• Newton, John N.
• Farrar, Jeremy
• Diamond, Ian
• Rourke, Emma
• Howarth, Alison
• Marsden, Brian D.
• Hoosdally, Sarah
• Jones, E. Yvonne
• Stuart, David I.
• Crook, Derrick W.
• Peto, Tim E. A.
• Pouwels, Koen B.
• Walker, A. Sarah
• Eyre, David W.

Titel

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Ist Teil von

• Nature communications, 2021-10, Vol.12 (1), p.6250-6250, Article 6250

Ort / Verlag

London: Nature Publishing Group UK

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2 infection can inform subsequent protection and risk of reinfection, however large-scale representative studies are limited. Here we estimated antibody response after SARS-CoV-2 infection in the general population using representative data from 7,256 United Kingdom COVID-19 infection survey participants who had positive swab SARS-CoV-2 PCR tests from 26-April-2020 to 14-June-2021. A latent class model classified 24% of participants as ‘non-responders’ not developing anti-spike antibodies, who were older, had higher SARS-CoV-2 cycle threshold values during infection (i.e. lower viral burden), and less frequently reported any symptoms. Among those who seroconverted, using Bayesian linear mixed models, the estimated anti-spike IgG peak level was 7.3-fold higher than the level previously associated with 50% protection against reinfection, with higher peak levels in older participants and those of non-white ethnicity. The estimated anti-spike IgG half-life was 184 days, being longer in females and those of white ethnicity. We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies. Most people who are infected with SARS-CoV-2 seroconvert within a few weeks, but the determinants and duration of the antibody response are not known. Here, the authors characterise these features of the immune response using data from a large representative community sample of the UK population.